skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Critical appraisal of the differential effects of antihypertensive agents on arterial stiffness

Review

(2406) Views  (865) Full article downloads

Authors: Francesca Kum, Janaka Karalliedde

Published Date June 2010 Volume 2010:3 Pages 63 - 71
DOI: http://dx.doi.org/10.2147/IBPC.S6651

Francesca Kum, Janaka Karalliedde

Unit for Metabolic Medicine, Cardiovascular Division, Kings College-Waterloo Campus, King’s College London, United Kingdom

Abstract: Increased central arterial stiffness, involving accelerated vascular ageing of the aorta, is a powerful and independent risk factor for early mortality and provides prognostic information above and beyond traditional risk factors for cardiovascular disease (CVD). Central arterial stiffness is an important determinant of pulse pressure; therefore, any pathological increase may result in left ventricular hypertrophy and impaired coronary perfusion. Central artery stiffness can be assessed noninvasively by measurement of aortic pulse wave velocity, which is the gold standard for measurement of arterial stiffness. Earlier, it was believed that changes in arterial stiffness, which are primarily influenced by long-term pressure-dependent structural changes, may be slowed but not reversed by pharmacotherapy. Recent studies with drugs that inhibit the renin–angiotensin–aldosterone system, advanced glycation end products crosslink breakers, and endothelin antagonists suggest that blood pressure (BP)-independent reduction and reversal of arterial stiffness are feasible. We review the recent literature on the differential effect of antihypertensive agents either as monotherapy or combination therapy on arterial stiffness. Arterial stiffness is an emerging therapeutic target for CVD risk reduction; however, further clinical trials are required to confirm whether BP-independent changes in arterial stiffness directly translate to a reduction in CVD events.

Keywords: aortic pulse wave velocity, augmentation index, blood pressure, renin–angiotensin–aldosterone system








Readers of this article also read:

Antihypertensive effects of astaxanthin
Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension
Comparative assessment of angiotensin receptor blockers in different clinical settings
Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice
De-stiffening drug therapy and blood pressure control
Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination
Evidence-based approach for managing hypertension in type 2 diabetes
Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction
Long-term use and tolerability of irbesartan for control of hypertension
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University